降脂药物与神经认知功能：系统评价。
Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review.
机构信息
Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain.
Centro de Salud Jesús Marín, Murcia, Spain.
出版信息
In Vivo. 2020 Nov-Dec;34(6):3109-3114. doi: 10.21873/invivo.12144.
BACKGROUND/AIM: Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials.
MATERIALS AND METHODS
A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function.
RESULTS
Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo.
CONCLUSION
Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed.
背景/目的：降脂药物被认为会影响神经认知功能。本综述旨在根据临床试验，提供有关这些药物影响神经认知功能的最新证据。
材料和方法
根据 PRISMA（系统评价和荟萃分析的首选报告项目）指南，通过 PubMed、EMBASE 和 Cochrane 数据库对 2015 年至 2020 年的原始研究进行了系统搜索。这些试验纳入了大量患者，并在世界不同地区进行。使用的术语有胆固醇、降脂药物、他汀类药物和认知功能。
结果
符合纳入标准的随机试验有 11 项。这些试验纳入了患有心血管疾病的患者。具体来说，对冠心病、冠心病风险等效物和高胆固醇血症患者进行了测试。试验包括依洛尤单抗、阿利罗单抗、他汀类药物、依折麦布或安慰剂。
结论
降脂药物似乎对神经认知功能没有显著影响，但需要对此进行专门的进一步研究。
Zotero 插件